New perspectives in neurosteroid action: open questions for future research by Rainer Rupprecht
OPINION ARTICLE
published: 19 September 2014
doi: 10.3389/fncel.2014.00268
New perspectives in neurosteroid action: open questions
for future research
Rainer Rupprecht*
Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
*Correspondence: rainer.rupprecht@medbo.de
Edited by:
Valerio Magnaghi, Università Degli Studi di Milano, Italy
Reviewed by:
Alessandro Faroni, The University of Manchester, UK
Giulia Puja, Università degli Studi di Modena e Reggio Emilia, Italy
Keywords: neurosteroid, allopregnanolone, TSPO, GABA, ion channel
Neurosteroids are still a hot topic
in cellular and systemic neuroscience
although the first report on anaesthetic
actions of progesterone from Selye was
published already in 1941 (Selye, 1941).
It is a fascinating concept that endoge-
nous metabolites of progesterone such
as allopregnanolone and pregnanolone
are powerful allosteric modulators of
γ-aminobutyric acid type A (GABAA)
receptors. This at a first glance simple
principle created by nature raises several
questions that still are major challenges
for neurosteroid research. What is the
exact site of interaction of such neuros-
teroids with GABAA receptors? Is it really
a binding site with clear saturable bind-
ing kinetics or rather an interaction site?
Recent studies show that photolabeling of
amino acids in the third transmembrane
domain of the β3 subunit of the GABAA
receptor by neurosteroid analogs is feasi-
ble (Chen et al., 2012) but does this really
prove a binding site? What makes the dif-
ference in the regulation of GABAergic
neurotransmission between the mod-
ulation by a 3α-reduced neurosteroid
such as allopregnanolone and a benzo-
diazepine? Both are positive allosteric
modulators of GABAA receptors and
enhance GABAergic neurotransmission
but there appear to be great differences
with regard to abuse liability and tol-
erance development (Rupprecht et al.,
2009). Do they merely target different sub-
unit compositions? An argument against
this hypothesis is that allopregnanolone
does not necessarily need a refined sub-
unit composition to exert its actions, a
β subunit is sufficient (Puia et al., 1990;
Rupprecht and Holsboer, 1999). Thus, a
more fascinating novel research area could
be to identify what neuronal networks ulti-
mately are targeted by either 3α-reduced
neurosteroids or benzodiazepines. Do
such neurosteroids and benzodiazepines
recruit a different composition of post-
and extrasynaptic GABAA receptors? For
example, future studies employing volt-
age sensitive dye imaging might address
such questions. To what extent receptors
other than GABAA receptors are involved
in neurosteroid action?
As a more systemical approach neu-
roimaging studies in humans, e.g., by
means of functional magnetic resonance
tomography (fMRI), might compare the
brain areas involved after administra-
tion of benzodiazepines (Leicht et al.,
2013) with neurosteroids such as allopreg-
nanolone. As such, a major issue of future
research in this area should be the elucida-
tion of the mechanisms of action of neu-
rosteroids both at the molecular, cellular
and brain network level.
Another important area of research is
the role of neurosteroids such as allo-
pregnanolone for normal and patholog-
ical behavior in animals and humans
and for neuropsychiatric disorders. It
is evident from many preclinical stud-
ies that neurosteroids modulate anxiety-
related behavior but nevertheless many
issues are far from being understood. For
example, what is the role of various neu-
rosteroids with a different receptor pro-
file acting in concert, e.g., pregnenolone
and allopregnanolone? What about con-
centration and time dependency of neu-
rosteroid effects? It may well be that such
phenomena affect both physiological and
pathological conditions. For example, it
has been shown that negative mood symp-
toms may occur in women with premen-
strual dysphoric disorder (PMDD) during
the luteal phase of the menstrual cycle
when progesterone and allopregnanolone
levels usually are high (Bäckström et al.,
2014) which has to be reconciled with the
known anxiolytic effects of moderate to
high concentrations of allopregnanolone.
Moreover, in such patients there is an
apparent discordance between the sensi-
tivity to diazepam and allopregnanolone
with decreased sensitivity to diazepam,
whereas sensitivity to allopregnanolone
is increased (Bäckström et al., 2014).
A widely neglected research area is the
role of isomers which acts as functional
antagonists of allopreganolone, for exam-
ple its 3β epimer (3β, 5α-pregnanolone).
All these compounds finally act in concert
in the modulation of rodent and human
behavior. An example for such an altered
equilibrium of steroid composition is the
prominent decline in 3α-reduced neuros-
teroids after challenge with sodium lactate
or cholecystokinin tetrapeptide (CCK-4)
in patients with panic disorder together
with a marked increase in the 3β-reduced
isomer (Ströhle et al., 2003), which
may result in a decreased GABAergic
tone related to pathophysiology of panic
attacks. Moreover, studies investigating
the composition of neurosteroid pro-
files in neuropsychiatric disorders dur-
ing differential psychopathological states
are rare and need further elaboration.
It is not surprising that neurosteroids
such as allopregnanolone play a role in
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the pathophysiology of mood disorders
(Schüle et al., 2014) and particularly for
women (Schiller et al., 2014).
Besides their neuromodulatory poten-
tial a major issue is whether endogenous
neurosteroids or synthetic neurosteroid
derivatives can be used as novel thera-
peutic agents for the treatment of neu-
ropsychiatric disorders. Ganaxolone is a
first example of a synthetic 3α-reduced
neurosteroid which is under investiga-
tion for the treatment of epilepsy, e.g.,
infantile spams (Riikonen, 2014). Another
attractive area of research is the use of
neurosteroidogenic compounds to pro-
mote endogenous neurosteroidogenesis.
Observations came from both preclini-
cal and clinical studies that for example
antidepressants such as selective serotonin
reuptake inhibitors (SSRIs) or mirtazap-
ine (Pinna et al., 2006; Schüle et al., 2014)
may enhance neurosteroidogenesis prob-
ably through interference with neuros-
teroidogenic enzymes. Moreover, ligands
of the translocator protein 18 kDa (TSPO)
have recently gained considerable atten-
tion as putative novel therapeutic agents
in neuropsychopharmacology (Rupprecht
et al., 2010). Numerous reports sug-
gest that they promote the transport of
cholesterol to the mitochondrial matrix
thereby initiating neurosteroidogenesis,
although recently the requirement of
TSPO for steroidogenesis has been ques-
tioned (Morohaku et al., 2014; Tu et al.,
2014). TSPO ligands are used as molecular
imaging tools for assessing brain damage
and microglia activation in positron emis-
sion tomography (PET) studies and have
been suggested to exert potential beneficial
effects in numerous preclinical investiga-
tions, for example peripheral nerve lesions
(Rupprecht et al., 2010), neuropathic pain
(Patte-Mensah et al., 2014), Alzheimer’s
disease (Chua et al., 2014), and retinal
damage (Karlstetter et al., 2014). First
clinical studies suggest that TSPO lig-
ands, e.g., olesoxime, represent a therapeu-
tic option in amyotrophic lateral sclerosis
(Rupprecht et al., 2010). Moreover, TPSO
ligands such as XBD173 or etifoxine may
act as anxiolytic agents in clinical studies
with a more favorable side effect profile
than that of benzodiazepines (Rupprecht
et al., 2009, 2010). It is intriguing that eti-
foxine is available in France since many
years for the treatment of adjustment anx-
iety disorder. This shows that it is feasi-
ble to develop TSPO ligands for clinical
indications with a favorable side effect
profile.
In conclusion, neurosteroids, e.g., allo-
pregnanolone, and neurosteroidogenic
compounds such as TSPO ligands still
represent a challenging area of research
that has the potential to further eluci-
date the physiology of rodent and human
behavior, the pathophysiology of neu-
ropsychiatric diseases and to open the
door for novel treatment avenues in
neuropsychopharmacology.
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